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SUMMARY
Introduction: Gram-negative bacillus Stenotrophomonas maltophilia is resistant to drugs (multi-drug resistance-MDR) and it can be 
isolated from nature. Treatment of the infections resulting from S. maltophilia could be problematic due to multi-resistance. 
Materials and Methods: 72 S. maltophilia strains isolated from clinical samples were included into the study. Sensitivity was determined 
using Tigecycline and Colistin E-test MIC method performed in the Clinical Microbiology laboratory of Baskent University, Medical Faculty 
between 2010 and 2014. 
Results: In our study, colistin MIC range was found as 0.016-8 mg/L. MIC50  and  MIC90 values were determined respectively as 1.5 
mg/L and 12 mg/L. Tigecycline MIC range was 0-96 mg/L, and MIC 50 was 0.19 mg/L and MIC 90 was 1.5 mg/L. Furthermore, one 
tigecycline resistant strain was detected.
Conclusion: We believe that the determination of novel treatments and protocols and their standardization using multidisciplinary 
approaches can facilitate to cope with problematic and resistant nosocomial infections developed by S. maltophilia. 
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Giriş: Stenotrophomonas maltophilia gram-negatif bir basil olup çok ilaça dirençli bir mikroorganizmadır. Tedavi seçenekleri birçok in 
vitro çalışma sonucu ve klinik deneyim neticesinde dikkate alınmalıdır.
Geliş	Tarihi/Received:	08/04/2015	-	Kabul	Ediliş	Tarihi/Accepted:	19/02/2018
In Vitro Susceptibility of Tigecycline and Colistin Against Stenotrophomonas maltophilia 
26 FLORA 2018;23(1):25-30
INTRODUCTION
Stenotrophomonas maltophilia is an important 
microorganism causing nosocomial infections and 
is an opportunistic microorganism which can be 
isolated from nature as well as from clinics[1]. It 
can be frequently isolated from the oropharyngeal 
and respiratory secretions of adults. S. maltop-
hilia can cause health-care associated infections 
especially in the Intensive Care Units (ICU) of 
hospitals[2].
S. maltophilia, is known to have multi-drug 
resistance (MDR). It can lead to infections such 
as meningitis, ocular infections, and endocarditis 
particularly in patients with comorbidities. The 
morbidity and mortality (between 20% and 70%) 
rate is high with S. maltophilia infections and the 
highest rates can be observed in patients recei-
ving inappropriate antibiotic therapy[3]. S. maltop-
hilia is intrinsically resistant to various antibiotics 
since it contains inhibitory mechanisms such as 
inactivation enzymes for beta-lactamases, aminog-
lycoside acetyl transferase and erythromycin and 
genes encoding efflux pumps. The treatment of 
S. maltophilia infections is problematic due to its 
resistance to various types of antibiotics including 
carbapenems which are currently being used in 
hospitals[4,5]. S. maltophilia infections can be tre-
ated using trimethoprim-sulfamethoxazole (TMP/
SMX). There are also other alternative antibi-
otics (such as ceftazidime, ticarcillin-clavulanate, 
minocycline, tigecycline, fluoroquinolones, and the 
polymyxins) that can be used. Treatments are 
being developed based on existing experiences 
with laboratory work, and therapeutic methods 
are developed on clinical trials[6]. In order to 
treat MDR S. maltophilia infections, alternative 
drugs should be investigated. In this study, using 
the MIC technique, we aimed to test the in vitro 
tigecycline and colistin activity on S. maltophilia 
strains isolated from clinical samples. 
MATERIALS and METHODS 
The strains were isolated from clinical samp-
les in Baskent University Medical Faculty Clinical 
Microbiology laboratory between 2010 and 2014 
and were included into the study. Bacteria identi-
fication was performed using either classical met-
hods (growth and morphological features observed 
upon culturing bacteria in a 5% sheep blood agar 
and eosin methylene blue (EMB) agar, features 
of bacteria observed by staining them with Gram 
stain, and performing the catalase and oxidase 
tests) or novel techniques such as using gram-ne-
gative bacteria identification cards in the Vitek2 
(bioMerieux) fully automated microbial identifica-
tion system. Blood culture samples were studied 
in the fully automated BacT/Alert 3D (bioMe-
rieux) blood culture system. Clinical Laboratory 
Standards Institute (CLSI) disk diffusion method 
was used to determine antibiotic sensitivity[7]. As 
recommended by CLSI, plates were checked after 
16-20 hours of incubation at 35 + 2°C. They 
were incubated for an additional 24 hours at 35 
+ 2°C and checked again in the end of the in-
cubation. Pseudomonas aeruginosa ATCC 27853 
strains were used as control strains and MIC 
sensitivity was between the range of 0.5-4[7].
E-Test
Isolates were cultured at 37°C for 18 hours in 
Eosin-Methylene Blue (EMB) agar (Becton Dickin-
son, Sparks, USA). The 0.5 (108 cfu/mL) McFar-
land was inoculated on BBL Mueller-Hinton agar 
Materyal ve Metod: Başkent Üniversitesi Tıp Fakültesi Klinik Mikrobiyoloji laboratuvarımızda 2010-2014 yılları arasında klinik izolat-
lardan izole edilen 72 suşta tigesiklin ve kolistin E-test yöntemiyle minimum inhibitör konsantrasyonu (MİK) yöntemiyle duyarlılıkları 
belirlenmiştir.
Bulgular: Çalışmamızda kolitsin MİK aralığı 0.016-8 mg/L aralığında bulunmuş olup MİK50= 1.5 mg/L ve MİK90= 12 mg/L olarak 
belirlemiştir. Tigesiklin MİK aralığı 0-96 mg/L aralığında bulunmuş olup MİK50= 0.19 mg/L ve MİK90= 1.5 mg/L olarak belirlemiş olup 
bir tane dirençli suş saptanmıştır.
Sonuç: S. maltophilia ile gelişen hastane infeksiyonları ile mücadelede daha geniş çalışmalar ve multidisipliner yaklaşımlarla yeni tedavi 
seçeneklerinin belirlenmesi ve yeni protokollerin oluşturulup standardize edilmesi sorunlu ve dirençli mikroorganizmalar ile mücadelede 
bizlere yardımcı olabileceği kanaatindeyiz.
Anahtar Kelimeler: Stenotrophomonas maltophilia; Tigesiklin; Kolistin; E-test
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(MHA) (Becton Dickinson, Sparks, USA) plates. 
Furthermore, E-test strips for tigecycline or colis-
tin (bioMérieux SA, France) were incubated with 
isolated bacteria. The MIC value of the inhibition 
zone in the agar culture was determined after 
18 hours of incubation at 35°C. Even though 
the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) states that the MIC 
threshold of the Enterobactericeae for tigecycline 
antibiotic is > 2 µg/mL, there is no value de-
termined for S. maltophilia strains. According to 
the literature, the sensitivity threshold value was 
detected as ≤ 2 µg/mL for S. maltophilia[7,8].
RESULTS
72 S. maltophilia strains were isolated from 
the clinical sample cultures of hospitalized pa-
tients (collected for bacteriological examination) 
in Baskent University Medical Faculty hospital 
between January 2010 and December 2014. The 
distribution of these strains according to clinical 
samples can be seen in Table 1. 
In our study, colistin MIC range was found 
as 0.016-8 mg/L. MIC50 and MIC90 values were 
determined respectively as 1.5 mg/L and 12 
mg/L. Tigecycline MIC range was 0-96 mg/L, 
and MIC50 was 0.19 mg/L and MIC90 was 
1.5 mg/L. Furthermore, one tigecycline resistant 
strain was detected. MIC sensitivities of the mic-
roorganisms and the MIC ranges of the control 
strains were shown in Table 2.
DISCUSSION 
S. maltophilia infections have been diagnosed 
particularly in the ICU of hospitals and the pat-
hogen is known as opportunistic. The number of 
antibiotics which can be used to treat these infec-
tions is limited due to resistance[9]. S. maltophilia 
infections are commonly observed in patients 
who are severely debilitated or immunocompro-
mised due to some kind of comorbidity[10]. There 
are some factors (such as advanced age, pre-
maturity, previous operations, diabetes mellitus, 
malignancy, implementation invasive interventions, 
stay in ICU, previously used broad-range beta-lac-
tam, aminoglycoside or fluoroquinolone antibiotics) 
which can facilitate S. maltophilia infections in 
in-patients[11]. The rate of S. maltophilia strains 
isolated from a hospital is generally between 
4% and 8%[12]. The mortality rate is quite high 
(between 20% and 70%) in patients who have S. 
maltophilia infection[3]. The mortality rate is over 
50% particularly in bacteremia[11]. 
Although antibiotic resistance is a diverse 
problem, the combination of TMP/SMX is 
primarily preferred to treat S. maltophilia 
infections. Piperacillin, fluoroquinolones (e.g., 
levofloxacin and moxifloxacin), and tetracycline 
derivatives (e.g., minocycline) can also be used. 
Antibiotic treatment should be arranged upon 
antibiograms[13]. The TMP/SMX resistance is 
Table 1. Examples of clinical isolates
Clinical
sample
Wound 
swab  
culture
Blood  
culture
Respiration secretion
(deep tracheal 
aspirates)
Abscess
culture
Urine
culture
Sputum
culture Body fluid Total
N 38 17 5 4 4 2 2 72
Table 2. Tigecycline and colistin MIC50, MIC90  
and control values determined by E-test 
E-test
MIC (µg/mL)
N Range MIC50 MIC90
S. maltophilia
Tigecycline 72 0.016-8 0.19 1.5
Colistin 72 0-96 1.5 12
Escherichia coli (control strain)
Tigescycline 0.64
Colistin 0.64
Pseudomonas aeruginosa (control strain)
Tigecycline ----
Colistin 0.50
In Vitro Susceptibility of Tigecycline and Colistin Against Stenotrophomonas maltophilia 
28 FLORA 2018;23(1):25-30
reported as around 10% in Europe[14]. The 
limitation of our study was we that could not 
differentiate colonization from infection. 
In order to compare the antibiotic activity of 
different bacteria (for Enterobacteriaceae, ≤ 2/≥ 
8 µg/mL for S/R determined by USA-FDA), 
tigecycline was given to Acinetobacter spp. and 
S. maltophilia[15]. In our study, we examined the 
effectivity of tigecycline and colistin antibiotics 
on S. maltophilia using the MIC method. The 
activity of tigecycline against S. maltophilia 
was indicated (MIC50 0.5 µg/mL and MIC90 
2 µg/mL). The activity of tigecycline against 
S. maltophilia was between 89.3% and 98.3% 
and it could be inhibited at ≤ 2 µg/mL and 
furthermore, the activity of both TMP/SMX and 
colistin against S. maltophilia were respectively 
as 94.5% and 98.5%[16]. It was shown that the 
inhibition rate of the tigecycline activity against 
S. maltophilia was %92.3 at ≤ 2 µg/mL and the 
colistin activity against S. maltophilia was around 
%94.5[17]. Betriu et al. have shown that the MIC 
range of tigecycline for S. maltophilia was 0.25-8 
mg/L, the MIC50 and MIC90 values were found 
as 1 mg/L and 4 mg/L respectively and there 
was no resistant strain.
In a study of nosocomial pneumonia in which 
S. maltophilia was the causative agent, sensitivity 
to tigecycline in 102 strains was 80.4%[18]. In 
another study, all 40 S. maltophilia strains ob-
tained in contact lens-using cases were found to 
be susceptible to tigecycline[19]. In a study con-
ducted by Renteria et al., MIC50 value has been 
detected as 0.25 µg/mL and MIC90 value as 1 
µg/mL for tigecycline in S. maltophilia strains[20]. 
In a Hungarian study, 160 S. maltophilia strains 
have been found to have an MIC50 value of 0.5 
µg/mL and an MIC90 value of 2 µg/mL
[21]. In 
our study, these values  were 0.19 and 1.5 µg/
mL, respectively.
In a study of antimicrobial susceptibility of 
30 S. maltophilia strains resistant to TMP/SMX, 
only 37% of strains have been reported to be 
sensitive to levofloxacin and moxifloxacin, and all 
were resistant to colistin and tigecycline[22]. In 
our study, all strains were susceptible to TMP/
SMX. In a study investigating the change of in 
vitro colistin resistance according to years, 641 
S. maltophilia clinical isolates were evaluated. 
In this study, the resistance rate of colistin was 
8% in 1996, whereas it was 54% in 2013, an 
increase of 11.4 times[23]. In a Hungarian study, 
colistin MIC values  were very high (MIC50 value), 
and our results were quite satisfactory.
Colistin; a member of polymyxins, has been 
shown to be used in the treatment of the in-
fections related to MDR gram-negative bacteria. 
There is no MIC range for colistin and tigecycline 
according to CLSI and EUCAST guidelines. In 
line with the literature, we showed that the MIC 
range of tigecycline was 0-96 mg/L, MIC50 and 
MIC90 values were determined respectively as 
0.19 mg/L and 1.5 mg/L and there was only 
one resistant strain. Researchers have observed 
the tigecycline activity against S. maltophilia bac-
teria[24]. Unlike other studies, we demonstrated 
that colistin MIC range was 0.016-8 mg/L, and 
we calculated the MIC50 and MIC90 values re-
spectively as 1.5 mg/L and 12 mg/L. Further-
more, we also detected one resistant strain.
Even though the susceptibility testing of colis-
tin is not reliable, it is still important in the treat-
ment of infections associated with MDR gram-neg-
ative bacilli[25]. Regarding colistin, MIC values of 
P. aeruginosa and other non-Enterobacteriaceae 
(susceptible MIC, ≤ 2 mg/L; intermediate MIC, 4 
mg/L; resistant MIC, ≥ 8 mg/L) are determined 
by CLSI. On the other hand, colistin treatment 
procedures have not yet been clarified by CLSI; 
particularly for the colistin-resistant S. maltophilia 
isolates[7,25]. In the literature, the MacABCsm 
efflux pump in S. maltophilia has recently been 
shown to confer intrinsic resistance to antimicro-
bials [aminoglycosides, macrolides, and polymyxin 
B and polymyxin E (colistin)] and to play an im-
portant role in regulating oxidative and envelope 
stress tolerance and biofilm formation[26]. 
Due to increased resistance to antibiotics, 
colistin has become popular in the treatment 
of infections due to MDR pathogens. Tan et 
al. have indicated that all isolated S. maltophilia 
strains were resistant to colistin (MIC90 ≥ 128 
mg/L)[27]. 
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To conclude, tigecycline can be a new active 
agent that can be used for infections associated 
with gram-negative, gram-positive as well as an-
aerobic pathogens[24]. We generally support the 
idea that the determination of novel treatments 
and new protocols and their standardization should 
be ensured by using multidisciplinary approaches 
that can facilitate to cope with problematic and 
resistant nosocomial infections developed by S. 
maltophilia. 
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